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Summary
Background: Propofol is often used for procedural sedation in children undergoing
gastrointestinal endoscopy. Reliable assessment of the depth of hypnosis during the
endoscopic procedure is challenging. Processed electroencephalography using the
Narcotrend Index can help titrating propofol to a predefined sedation level.
Aims: The aim of this trial was to investigate the impact of Narcotrend Index-
guided titration of propofol delivery on the speed of recovery.
Methods: Children, aged 12-17 years, undergoing gastrointestinal endoscopy under
procedural sedation, had propofol delivered via target controlled infusion either
based on Narcotrend Index guidance (group NI) or standard clinical parameters
(group C). Sedation was augmented with remifentanil in both study groups. The pri-
mary endpoint of this study was to compare the speed of fulfilling discharge criteria
from the operating room between study groups. Major secondary endpoints were
propofol consumption, discharge readiness from the recovery room, hypnotic depth
as measured by the Narcotrend Index, and adverse events.
Results: Of the 40 children included, data were obtainable from 37. The time until
discharge readiness from the operating room was shorter in group NI than in group
C, with a difference between medians of 4.76 minutes [95%CI 2.6 to 7.4 minutes].
The same accounts for recovery room discharge times; difference between medians
4.03 minutes [95%CI 0.81 to 7.61 minutes]. Propofol consumption and the percent-
age of EEG traces indicating oversedation were higher in group C than in group NI.
There were no significant adverse events in either study group.
Conclusion: Narcotrend Index guidance of propofol delivery for deep sedation in
children aged 12-17 years, underdoing gastrointestinal endoscopy results in faster
recovery, less drug consumption, and fewer episodes of oversedation than dosing
propofol according to clinical surrogate parameters of depth of hypnosis. The results
of this study provide additional evidence in favor of the safety profile of propofol/
remifentanil for procedural sedation in adequately selected pediatric patients.
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1 | INTRODUCTION
Gastrointestinal endoscopy in pediatric patients can be performed
either under general anesthesia or procedural sedation and analgesia.
When performed under procedural sedation and analgesia, deep seda-
tion 1 is required, which is often indistinguishable from minimal anes-
thesia,2 because assessment of depth of hypnosis and titration of
hypnotic drugs to a precisely predefined endpoint remain challenging.3
Procedural sedation for pediatric gastrointestinal endoscopy
using a continuous infusion of propofol can be regarded as safe and
effective, as long as sedation is given by sufficiently trained health-
care providers and in carefully selected patients.4-6 The addition of
low-dose continuous remifentanil to provide analgesia and augment
propofol effect can be considered effective and safe.7,8
Delivering deep sedation or minimal anesthesia to a child with an
unsecured airway requires an exceptional high level of situational
awareness on the side of the pediatric anesthesiologist. Objective
measures of hypnotic depth can provide the anesthesiologist with
important information regarding hypnotic drug effect, ultimately
leading to improved patient safety.
Electroencephalographic NarcotrendTM monitoring has been shown
to be a useful tool to assess the depth of hypnosis in pediatric patients
receiving procedural sedation for gastrointestinal endoscopy.9 We
hypothesized that NarcotrendTM monitoring can help titrating propofol
delivered by target controlled infusion (TCI) to predefined sedation
endpoints, ultimately resulting in shorter discharge times from the
operating room, while avoiding both awareness with recall and too
deep sedation with possible cardiorespiratory compromise.
The primary endpoint of this prospective randomized controlled
trial was to compare the speed of recovery from Narcotrend-guided
delivery of propofol for pediatric gastrointestinal endoscopy to stan-
dard practice using clinical assessment of hypnotic depth. Major sec-
ondary endpoints were comparison of total propofol consumption,
discharge readiness from the post anesthesia care unit, post hoc
comparison of hypnotic depth as measured by Narcotrend, and
adverse events.
2 | MATERIALS AND METHODS
This single center prospective randomized controlled double-blind
trial was approved by the IRB of the Erasmus University Medical
Center, Rotterdam, The Netherlands (MEC-2013-180; July 11, 2013)
and performed in accordance with the Declaration of Helsinki.
The study was registered in the Nederlands Trial Register on
May 12, 2014; trial number NTR4593; principle investigator Dr.
Frank Weber. Patient inclusion started on May 27, 2014. Written
informed consent was obtained from all patients and their parents or
legal representatives. This manuscript adheres to the 2010 CON-
SORT guidelines (see Figure 1).
Pediatric patients aged 12-17 years, scheduled for upper and
lower gastrointestinal endoscopy procedures under procedural
sedation and analgesia, performed at Erasmus University Medical
Center—Sophia Children’s Hospital, Rotterdam, The Netherlands,
were eligible for inclusion. Allergies to propofol or remifentanil, any
contraindication to endoscopy performed under procedural sedation,
a body weight of more than 60 kg (limitation of the pediatric propo-
fol TCI model used), chronic use of drugs influencing the electroen-
cephalogram (EEG), and/or opioids and insufficient understanding of
the Dutch language were defined as primary exclusion criteria.
Patient request or unexpected need for an inhalation induction due
to significant difficulties to obtain intravenous access and any proce-
dural events requiring endotracheal intubation were defined as sec-
ondary exclusion parameters.
2.1 | Study procedures
Standard sedation monitoring equipment according to departmental
standards (ECG, pulse oximetry, noninvasive blood pressure, and
qualitative CO2 sampling via a nasal cannula) was used.
Before initiation of sedation, all study patients were attached to
a NarcotrendTM EEG monitor (MT MonitorTechnik GmbH & Co. KG,
Bad Bramstedt, Germany) according to the manufacturer’s specifica-
tions. The Narcotrend records the frontal EEG to calculate a dimen-
sionless index of depth of hypnosis, the Narcotrend Index, ranging
from 0 (very deep hypnosis) to 100 (being fully awake). The Nar-
cotrend monitor records the EEG using 3 conventional ECG elec-
trodes and does not require device-specific EEG electrodes.
Narcotrend data were exported as Excel files for subsequent
analyses using the EEG ViewerTM software package (Version 1.6, MT
MonitorTechnik GmbH & Co. KG, Bad Bramstedt, Germany).
Propofol was administered using the Paedfusor TCI model 10 on
an AlarisTM PK Syringe Pump (CareFusion UK 306 Ltd, Basingstoke,
UK). The total amount of propofol (mg) infused during the endo-
scopy was noted for subsequent analysis.
What is already known about the topic
• Reliable continuous and nondisruptive assessment of the
depth of hypnosis during propofol sedation in pediatric
patients is challenging.
• Processed electroencephalography using the Narcotrend
Index of depth of hypnosis can help titrating propofol to
a desired sedation level during pediatric gastrointestinal
endoscopy.
What new information this study adds
• Narcotrend Index guidance of propofol delivery results in
significantly shorter recovery times, less drug consump-
tion, and fewer episodes of oversedation than standard
practice.
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Sedation was initiated using a stepwise increase (1 lg/mL) of
propofol every 15 seconds, until either a stable Narcotrend Index of
65  5 (Group NI), or a state of deep sedation, with the patient not
being rousable by mild tactile stimulation (Group C), was established.
When these milestones were reached, the endoscopy was allowed
to be started.
During the endoscopy, in patients randomized to group NI, propo-
fol was titrated in steps of 0.5 lg/mL to maintain a Narcotrend Index
of 65  5. We had to take care to keep the likelihood of unintended
episodes of intraprocedural awareness with recall as low as possible.
Therefore, and due to personal clinical experience of the principle
investigator, we aimed at NI values indicating a rather deep level of
sedation.11 We are aware that it is debatable whether our approach
should be called deep sedation or light anesthesia with an unsecured
airway. The latter definition might confuse readers; therefore, we
decided to call our approach procedural sedation and analgesia.
In patients randomized to group C, Narcotrend Index data were
unavailable to the pediatric anesthesiologist in charge. Propofol dos-
ing was entirely based on conventional clinical surrogate parameters
of depth of hypnosis, such as heart rate, blood pressure, and patient
movement. The same 0.5 lg/mL titration steps as in group NI were
applied to achieve and maintain good endoscopy conditions.
Remifentanil was infused starting at a continuous rate of
0.025 lg/kg/min, irrespective of study group allocation. In case of
clinical signs of discomfort or purposeful movement, remifentanil
infusion was increased to 0.05 lg/kg/min, whereas in the event of a
respiratory rate of ≤10/min, the infusion rate was lowered to
0.01 lg/kg/min.
Patients were breathing spontaneously throughout the sedation
procedure, having oxygen 3 L/min applied via a nasal cannula.
Immediately after removal of the endoscope at the end of the
procedure, anesthetic drug infusions were discontinued. An investi-
gator who was blinded to patient group allocation entered the oper-
ating room and started to assess the patients’ course of recovery
from procedural sedation using the “Steward Recovery Score from
Anaesthesia”.12 Predefined criteria for discharge from the operating
room to the recovery room were responsiveness to stimulation,
good airway maintenance, and nonpurposeful movements, equaling
to a Steward score of 3 out of 6. The time interval between discon-
tinuation of propofol delivery and reaching a Steward score of 3 was
defined as the primary outcome parameter of this trial.
The following secondary outcome parameters were defined:
Propofol consumption (mg/kg/h) during the endoscopy, the time
interval between the end of the procedure and meeting discharge
Assessed for eligibility (n = 64)Enrollment
Randomized (n = 40)
Excluded (n = 24)
Not meeting inclusion criteria (n = 9)
Declined to participate (n = 15)
Intervention Group (Narcotrend Index guidance)
Allocated to intervention (n = 20)
Received allocated intervention (n = 19)
Did not receive allocated intervention (n = 1)
(Request for inhalation induction)
Control Group (Standard practice)
Allocated to intervention (n = 20)
Received allocated intervention (n = 20)
Did not receive allocated intervention (n = 0)
Allocation
Lost to follow-up (n = 0)
Discontinued intervention (n = 2)
Lost to follow-up (n = 0)
Discontinued intervention (n = 2)
Insuficient airway stability (n = 1)
Protocol violation (n = 1)
Follow-up
Analysed (n = 17)
Excluded from analysis (n = 3)
Analysed (n = 17)
Excluded from analysis (n = 3)
Did not receive allocated intervention (n = 1)
Discontinued intervention (n = 2)
Analysis
F IGURE 1 Study flow diagram according to the CONSORT 2010 statement
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criteria from the recovery room (Steward score of 6), the distribu-
tion of Narcotrend Index values during the endoscopy (within,
below, or above the target range of 65  5), the incidence of
recall of events during the endoscopy (assessed by a Brice
interview 13 on 3 occasions), the assessment of the endoscopy
conditions by the pediatric gastroenterologist (good—acceptable—
difficult) and adverse effects. We had also planned an economic
analysis (cost minimization analysis). Unfortunately, due to legal
restrictions regarding the publication of economic data, which we
were not aware of when we designed this study, we were unable
to perform that analysis.
2.2 | Randomization
Patients were allocated to the intervention or the control group
according to a block-randomization scheme (6-8-8-8-10 = 40), gen-
erated by the principle investigator (F.W.) using the website Ran-
domization.com (http://www.randomization.com). F.W. was the
anesthesiologist who delivered procedural sedation to all study
patients and was therefore not blinded regarding patient allocation
to study groups.
2.3 | Power analysis
To detect a difference of 30% less time to meet discharge criteria
from the operating room (Steward Score of 3) in the intervention
group, with an alpha level of significance fixed at .05 and a beta
level of .20, the number of patients required in each study group
was 18. This expected difference was based both on previously pub-
lished data in patients undergoing procedures under general anesthe-
sia 11 or sedation 14 and personal experience of the principle
investigator (F.W.) of this study. In order to compensate for possible
dropouts due to any kind of protocol violation, a sample size of
2 9 20 study patients was chosen. Sample size was calculated both
for both a Student’s t test (n = 2 9 17 subjects) and a Mann-Whit-
ney U test (n = 2 9 18 subjects) using G*Power 3.1.15
2.4 | Statistical analysis
Data analysis was performed by all authors using Prism 7 for Mac OS
X (Version 7.0C, GraphPad Software Inc., La Jolla, CA, U.S.A.). Contin-
uous data were tested for normality using the D’Agostino and Pear-
son omnibus normality test. Intergroup comparisons of continuous
data were performed using an unpaired T test or a Mann-Whitney U
test. Categorical data were compared by a chi-square or Fisher’s
exact test. Continuous data are presented as mean(sd) or median
[95% CI] as appropriate. P-values <.05 were considered significant.
3 | RESULTS
Between May 2014 and October 2015, 40 pediatric patients
were recruited. One patient who was already randomized to
group NI asked for an inhalation induction and was therefore
excluded from participation in the study. Another patient, also
allocated to group NI, unexpectedly showed clinical signs of
insufficient airway stability after starting procedural sedation. In
order to prevent this patient from significant airway obstruction,
we decided to switch to general anesthesia with endotracheal
intubation, resulting in secondary exclusion. In a third patient
randomized to group NI, propofol/remifentanil had to be adminis-
tered regardless of Narcotrend Index values due to excessive
involuntary patient movement during the endoscopy, resulting in
secondary exclusion due to protocol violation. Patient and proce-
dural data of the remaining 37 study participants who completed
the study are presented in Table 1. Data analysis was performed
per protocol.
Regarding the duration of the endoscopic procedures, there was
no evidence of a difference between study groups (group NI
20.7 minutes, group C 34.4 minutes); the difference between medi-
ans was 13.6 [6.02 to 19.8] minutes, P = .479.
The time interval between the end of the endoscopy (stop
propofol delivery) and meeting the criteria for being discharged from
the operating room was significantly shorter in group NI than in
group C, with a difference between medians of 4.76 minutes [95%
CI 2.6 to 7.4 minutes], P = .0006. For details see Figure 2.
Propofol consumption during the endoscopic procedure was
lower in group NI than in group C, with a difference between medi-
ans of 2.1 [95% CI 0.1 to 4] mg/kg/h, P = .046.
The time interval from discontinuation of anesthetic drug deliv-
ery until discharge criteria from the recovery room were met (Ste-
wart score 6) was shorter in group NI than in group C, with a
difference between medians of 4.03 minutes [95% CI 0.81 to
7.61 minutes].
Intergroup comparison of the distribution of Narcotrend Index
values (within, above, or below the target range of 65  5) revealed
significant intergroup differences on all 3 levels. The percentage of
Narcotrend Index values below the target range was lower in group
NI than in group C, with a difference between medians of 63% [95%
CI 35 to 68%]. Regarding the values within the target range, the per-
centage in group NI was higher than in group C, with a difference
between medians of 37% [95% CI 19 to 41%]. The same accounts
for the percentage of values above the target range, with a
TABLE 1 Patient and procedure characteristics
Group NI Group C
Age (y) 15.2 (1.6) 15.0 (1.8)
Weight (kg) 53.7 (8.3) 49.0 (8.0)
Gender (female/male) 7/10 11/9
Type of procedure (n)
EGD 2 5
Ileocolonoscopy 13 9
EGD and Ileocolonoscopy 2 6
Data are presented as mean(sd) or absolute values.
C, control; EGD, esophagogastroduodenoscopy; NI, Narcotrend Index.
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difference between medians of 26% [95% CI 14 to 31]. For more
details see Figure 3.
Brice interviews revealed no episodes of awareness with recall
during the endoscopy in any patient.
Intergroup comparison of the pediatric gastroenterologists’
assessments of endoscopy conditions (good—acceptable—difficult;
Group NI: 16-1-0; Group C: 17-3-0) revealed no evidence of a dif-
ference. Compared to group C, the relative risk of being assigned to
‘acceptable’ in group NI was 0.39 [95% CI 0.059 to 2.27], P = .608.
There were no episodes of hypoxia in any patient. We observed
the following adverse events, all during the induction period, prior to
the start of the endoscopy: A jaw-thrust maneuver was required in 1
patient in group NI and 1 patient in group C. Four patients in group
C required face mask ventilation, all of them for less than 1 minute.
4 | DISCUSSION
The results of this study, comparing recovery times from procedural
sedation and analgesia for pediatric gastrointestinal endoscopy using
either EEG-directed propofol delivery or standard practice, provide
evidence of the additive value of Narcotrend Index monitoring on
the speed of recovery. This applies to meeting discharge criteria
from both the operating room (5.4 vs 10.2 minutes) and the recov-
ery room (8.1 vs 11.1 minutes). The accumulated decrease in dis-
charge time from the operating room during an entire endoscopy list
could be sufficient to include an additional short procedure.
We used TCI technology for propofol application. Propofol mean
effective concentrations (EC50) have been calculated in pediatric
patients for a variety of clinical endpoints and scenarios, among
them gastrointestinal endoscopy.8,16 McCormack et al17 investigated
the predictive value of propofol TCI on recovery from anesthesia in
children and reported no significant clinical advantage. In our study,
we used processed EEG as the leading variable to titrate propofol
via TCI. Another advantage of TCI is that during the induction,
propofol is injected slower than a usual manual induction bolus,
which helps to maintain spontaneous ventilation.18
Powers et al14 used the Bispectral Index (BIS) for titration of
propofol during procedural sedation in children. A mean propofol
dose of 31.2 mg/kg/h, calculated for the entire sedation period,
starting with the induction until completion of the endoscopy, was
necessary to achieve and maintain a BIS of 45. The average awak-
ening time, defined as eye opening, was 13.89 minutes. These data
are difficult to compare with ours for several reasons: A BIS of 45
is close to the lower end of the range recommended for mainte-
nance of general anesthesia (BIS 40-60) rather than for mainte-
nance of (deep) sedation. Using propofol as the sole agent is
furthermore different from our approach, where we used remifen-
tanil and propofol in combination. Like Powers et al, we failed to
keep our patients allocated to the intervention group within the
Narcotrend Index target range throughout the endoscopy. Nar-
cotrend Index-guided propofol titration resulted in a median[IQR]
percentage of 41[31 to 52] of Narcotrend Index values within the
target range of 60-70.
In our control group, as revealed by post hoc analysis of Nar-
cotrend Index data, this median percentage was as low as 4.5[0 to
17.3]. The percentages of Narcotrend Index values lower than the
target range, representing possible oversedation, were 32[17 to



















F IGURE 2 Recovery time (discharge readiness from operating
room). Individual data (dots) together with median and interquartile
range [Colour figure can be viewed at wileyonlinelibrary.com]


















F IGURE 3 Percentage distribution of Narcotrend Index values during
endoscopy. Individual data (dots) together withmedian and interquartile
range [Colour figure can be viewed atwileyonlinelibrary.com]
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to 100]% in the control group. The opposite was the case when
looking at Narcotrend Index values above the target range, repre-
senting possible undersedation (group NI: 26[14.5 to 35.5]%; group
C: 0[0 to 0.75]%).
Oversedation may be associated with cardiorespiratory compro-
mise, whereas under- sedation can cause intraprocedural awareness
with recall. During PSA with an unsecured airway, which, in patients
undergoing esophagogastroduodenoscopy is even inaccessible with-
out interrupting the procedure, airway compromise due to hypoven-
tilation is a significant safety issue, as opposed to patients under
general anesthesia, having their airway secured by an endotracheal
tube or a laryngeal mask. In our study, we did not encounter these
adverse events in any of our patients.
4.1 | Patient safety aspects
There is an ongoing debate about safety issues associated with deep
sedation for pediatric gastrointestinal endoscopy.4-6,19-22 This debate
is about drug safety, patient selection, care givers’ competencies,
and institutional issues. What our results add to the drug safety dis-
cussion is that Narcotrend Index-guided dosing of propofol, using
TCI technology, results in a significant reduction of episodes of
undesired oversedation, compared to conventional treatment proto-
cols. Though we strongly recommend our concept of deep sedation
for pediatric GE, using Narcotrend-guided propofol delivery, aug-
mented with remifentanil, we shall not forget mentioning that this
recommendation is only under the following prerequisites: Patients
have to be screened carefully regarding their eligibility for PSA.
Caregivers need to be sufficiently skilled in pediatric airway manage-
ment, including emergency situations. Institutions must be ade-
quately equipped to run a pediatric sedation program, regarding
both facilities and skilled personnel. Last but not least, it is our per-
sonal impression that delivering PSA in children requires an excep-
tional high level of situational awareness regarding all aspects of
patient safety and comfort. Close communication between the pedi-
atric gastroenterologist and the pediatric anesthesiologist is indis-
pensable.
This study was conducted in pediatric patients aged 12-17 years.
There is sufficient evidence from the scientific literature that pro-
cessed EEG provides us with reliable information regarding the DoH
in this patient age group.23,24 Care must be taken not to extrapolate
the results of this study to significantly younger children or even
infants. This is both due to the fact that young age is a known risk
factor when delivering PSA,19 and maturational aspects of the EEG,
which make DoH monitors less reliable in young children.23,24
4.2 | Shortcomings
Using DoH monitoring to titrate hypnotic drugs without feeling
uneasy about relying on the information provided by the DoH
monitor, needs at least some degree of experience in using that
technology. In our study, sedation was given by a single pedi-
atric anesthesiologist (F.W.), with long time experience in using
DoH monitoring in children. As already mentioned by Roizen
and Toledano,25 being accustomed to the use of certain tech-
nology in a certain group of patients improves outcomes in all
patients. There is thus a chance that propofol dosing in the
control group was slightly influenced by a “sub-conscious” influ-
ence of the experience derived from using DoH monitoring in
other patients before. To minimize the chance of learning-con-
tamination bias, patients randomized to group NI should their
sedation preferably have been given by an anesthesiologist
accustomed to the use of the Narcotrend, whereas the anesthe-
siologist responsible for patients randomized to group C should
have no experience at all in the use of DoH monitoring. Unfor-
tunately, we did not have enough research staff available to
perform the study that way.
It would have added significance to the results of our study if
we had effect site concentration TCI models available for both
propofol and remifentanil. Unfortunately, the plasma concentration
Paedfusor model is currently the only TCI algorithm registered for
use in pediatric patients in the Netherlands.
5 | CONCLUSIONS
In this prospective randomized controlled study, conducted in pedi-
atric patients aged 12-17 years, Narcotrend Index guidance of
propofol sedation for gastrointestinal endoscopy resulted in a signifi-
cantly faster recovery than standard practice relying on clinical surro-
gate parameters of hypnotic depth. In this patient age group and
clinical setting, NI guidance of procedural sedation can be regarded
as safe and effective.
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